LY 235959
new

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525525

CAS#: 137433-06-8

Description: LY 235959 is a competitive NMDA receptor antagonist.


Price and Availability

Size Price Shipping out time Quantity
10mg USD 310 2 Weeks
50mg USD 920 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-10-26. Prices are subject to change without notice.

LY 235959, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS docum ents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 525525
Name: LY 235959
CAS#: 137433-06-8
Chemical Formula: C11H20NO5P
Exact Mass: 277.1079
Molecular Weight: 277.26
Elemental Analysis: C, 47.65; H, 7.27; N, 5.05; O, 28.85; P, 11.17


Synonym: LY 235959; LY235959; LY-235959.

IUPAC/Chemical Name: 3-Isoquinolinecarboxylic acid, decahydro-6-(phosphonomethyl)-, (3S-(3alpha,4aalpha,6beta,8aalpha))-

InChi Key: STIRHCNEGQQBOY-QEYWKRMJSA-N

InChi Code: InChI=1S/C11H20NO5P/c13-11(14)10-4-9-3-7(6-18(15,16)17)1-2-8(9)5-12-10/h7-10,12H,1-6H2,(H,13,14)(H2,15,16,17)/t7-,8-,9+,10-/m0/s1

SMILES Code: O=C([C@H]1NC[C@]2([H])CC[C@H](CP(O)(O)=O)C[C@]2([H])C1)O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Rawls SM, Gomez T, Raffa RB. An NMDA antagonist (LY 235959) attenuates abstinence-induced withdrawal of planarians following acute exposure to a cannabinoid agonist (WIN 55212-2). Pharmacol Biochem Behav. 2007 Mar;86(3):499-504. Epub 2007 Jan 20. PubMed PMID: 17306870.

2: Gasior M, Borowicz K, Kleinrok Z, Starownik R, Czuczwar SJ. Anticonvulsant and adverse effects of MK-801, LY 235959, and GYKI 52466 in combination with Ca2+ channel inhibitors in mice. Pharmacol Biochem Behav. 1997 Apr;56(4):629-35. PubMed PMID: 9130287.

3: Bhargava HN. Enhancement of morphine actions in morphine-naive and morphine-tolerant mice by LY 235959, a competitive antagonist of the NMDA receptor. Gen Pharmacol. 1997 Jan;28(1):61-4. PubMed PMID: 9112078.

4: Borowicz KK, Gasior M, Kleinrok Z, Czuczwar SJ. Competitive NMDA-receptor antagonists, LY 235959 and LY 233053, enhance the protective efficacy of various antiepileptic drugs against maximal electroshock-induced seizures in mice. Epilepsia. 1996 Jul;37(7):618-24. PubMed PMID: 8681893.